First Wave BioPharma Management
Management criteria checks 2/4
First Wave BioPharma's CEO is James Sapirstein, appointed in Oct 2019, has a tenure of 4.58 years. total yearly compensation is $1.25M, comprised of 41.2% salary and 58.8% bonuses, including company stock and options. directly owns 1.83% of the company’s shares, worth $97.96K. The average tenure of the management team and the board of directors is 2.3 years and 4.6 years respectively.
Key information
James Sapirstein
Chief executive officer
US$1.2m
Total compensation
CEO salary percentage | 41.2% |
CEO tenure | 4.6yrs |
CEO ownership | 1.8% |
Management average tenure | 2.3yrs |
Board average tenure | 4.6yrs |
Recent management updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections
Jan 04AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients
Nov 30Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?
Nov 19CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$1m | US$514k | -US$16m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$8m |
Mar 31 2023 | n/a | n/a | -US$9m |
Dec 31 2022 | US$742k | US$480k | -US$15m |
Sep 30 2022 | n/a | n/a | -US$22m |
Jun 30 2022 | n/a | n/a | -US$57m |
Mar 31 2022 | n/a | n/a | -US$65m |
Dec 31 2021 | US$1m | US$480k | -US$85m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$74m |
Mar 31 2021 | n/a | n/a | -US$66m |
Dec 31 2020 | US$1m | US$463k | -US$42m |
Sep 30 2020 | n/a | n/a | -US$25m |
Jun 30 2020 | n/a | n/a | -US$15m |
Mar 31 2020 | n/a | n/a | -US$16m |
Dec 31 2019 | US$677k | US$102k | -US$15m |
Compensation vs Market: James's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Sapirstein (62 yo)
4.6yrs
Tenure
US$1,245,766
Compensation
Mr. James R. Sapirstein, R.Ph. M.B.A. has been an Independent Director of ZyVersa Therapeutics, Inc. since January 2023. He served as Interim Chief Executive Officer at Marizyme, Inc. since March 19, 2021...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Chairman | 4.6yrs | US$1.25m | 1.83% $ 98.0k | |
Chief Financial Officer | 2.2yrs | US$810.56k | 0.94% $ 50.5k | |
President | less than a year | no data | 0.76% $ 40.7k | |
Vice President of Regulatory Affairs | 2.3yrs | no data | no data | |
Senior Vice President of Corporate Development | 4.3yrs | no data | no data |
2.3yrs
Average Tenure
58yo
Average Age
Experienced Management: FWBI's management team is considered experienced (2.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Chairman | 4.6yrs | US$1.25m | 1.83% $ 98.0k | |
President | less than a year | no data | 0.76% $ 40.7k | |
Independent Director | 7.2yrs | US$150.85k | 0.00010% $ 5.3 | |
Independent Director | less than a year | no data | 0.022% $ 1.2k | |
Independent Director | 8.7yrs | US$146.02k | 0.97% $ 51.8k | |
Lead Independent Director | 9yrs | US$177.52k | 0.97% $ 51.9k | |
Independent Director | 2.8yrs | US$158.19k | 0% $ 0 |
4.6yrs
Average Tenure
65yo
Average Age
Experienced Board: FWBI's board of directors are considered experienced (4.6 years average tenure).